FindMyKOL
Clinical trialNCT06810934RecruitingPhase 1/2Interventional

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

NCT06810934 is a phase 1/2 interventional trial sponsored by Kara Chew. As of 21 Nov 2026, it is recruiting participants. It studies CoTend-BXBB, CoTend-s3BXBB and Placebo in COVID-19 and SARS-CoV-2 Infection. The registry lists an enrollment of 80 participants at 2 sites in 1 country. The registry lists a start date of 21 Oct 2025 and a primary completion date of 31 Dec 2027. 2 of its registered investigators have a FindMyKOL profile.

SponsorKara Chew →Enrollment80COVID-19SARS-CoV-2 Infection
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06810934
FieldValue
Registry IDNCT06810934
StatusRecruiting
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorKara Chew
Enrollment80
Registered sites2
Countries1
ConditionsCOVID-19 and SARS-CoV-2 Infection
DrugsCoTend-BXBB, CoTend-s3BXBB and Placebo
Start21 Oct 2025
Primary completion31 Dec 2027
Study completion31 Oct 2029
Last update posted18 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called "s3", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does "s3" lead to bigger, broader, and longer-lasting responses to the vaccine? 5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, or placebo. Participants will be monitored for side effects. Saliva, nasal, and blood samples will be collected and immune responses to the vaccine will be measured.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites, 2 recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 2 sites, 2 recruitingCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CoTend-BXBBCoTend-s3BXBBPlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06810934

Each answer restates registry values shown on this page.

What is NCT06810934?

NCT06810934 is a phase 1/2 interventional trial sponsored by Kara Chew. It studies CoTend-BXBB, CoTend-s3BXBB and Placebo in COVID-19 and SARS-CoV-2 Infection.

Is NCT06810934 recruiting?

As of 21 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.

Who leads NCT06810934?

The registry names Dennis Hartigan-O'Connor, MD, PhD (principal investigator, University of California, Davis), Kara Chew, MD, MS (principal investigator, University of California, Los Angeles) and Steven Deeks, MD (principal investigator, University of California, San Francisco) as overall officials.

Where does NCT06810934 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06810934 study?

The registered drug and biological interventions are CoTend-BXBB, CoTend-s3BXBB and Placebo.

When is NCT06810934 expected to complete?

The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 31 Oct 2029. The sponsor last updated the record on 18 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.